pharmaphorum

MAY 29, 2022

The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously-untreated advanced oesophageal cancer, encroaching on territory held by Merck & Co’s rival Keytruda. The pair of new approvals are based on the results of the CheckMate-648 trial, and are for Opdivo (nivolumab) paired with chemotherapy or BMS’ CTLA4 inhibitor Yervoy (ipilimumab) as first-line therapy for advanced or metastatic oesophageal squamous cell carc

FDA 59

FDA Chemotherapy 59

Colors Make me Happy

MAY 29, 2022

When I was the CEO for the SC Pharmacy Association, I would visit about 20 pharmacies a week. As I was waiting to meet with the team at each pharmacy, I watched each member of the community pharmacy team run from one end of the pharmacy to the next to answer the phones that did not stop ringing with calls from patients as well as providers, service the drive through customers, arrange for minute clinics as well as patient counseling, and take care of dozens of patients waiting in line for COVID-

Community Pharmacies 40

Community Pharmacies Documentation Hospitals Vaccines 40

Med Ed 101

MAY 29, 2022

ES is a 61-year-old female who is a resident in a long-term care facility. She has a history of drug abuse, early-onset dementia, GERD, chronic pain, and osteoarthritis. Her current medications include gabapentin 100 mg TID, donepezil 10 mg HS, omeprazole 20 mg in the morning, famotidine 20 mg in the evening, and acetaminophen 650 […]. The post Nitrofurantoin For Complicated UTI – Case Study appeared first on Med Ed 101.

Long-Term Care Facilities 40

Long-Term Care Facilities 40